Actively Recruiting
Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Pharmacokinetics of Single and Multiple Ascending Doses of EPX-100 in Healthy Adults
Led by Epygenix · Updated on 2026-10-16
88
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacokinetics of EPX-100 in healthy adult participants through a two-part study. Part 1 focuses on single ascending doses SAD of EPX-100, while Part 2 investigates multiple ascending doses MAD, including assessment of cardiac effects in each group. This randomized, double-blind, placebo-controlled study also includes a positive control to compare effects. Participants in Part 1 receive sequential single ascending doses of EPX-100 or matching placebo. In Part 2, participants receive EPX-100 twice daily for 13 days and a morning dose on Day 14, with placebo controls including moxifloxacin or its matching placebo in a crossover design. The study evaluates EPX-100s pharmacokinetics and safety during both single and multiple dose phases. During the trial, participants undergo various assessments including monitoring for treatment-emergent adverse events, pharmacokinetic sampling of plasma and urine, and electrocardiogram ECG evaluations to check cardiac intervals. The study tracks safety and tolerability up to Day 18 for Part 1 and Day 31 for Part 2. The total participation period varies depending on the study part and dosing schedule, with careful monitoring throughout.
CONDITIONS
Brief Title
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here